BiondVax Pharmaceuticals Ltd. (BVXV): Price and Financial Metrics


BiondVax Pharmaceuticals Ltd. (BVXV): $2.30

-0.04 (-1.71%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

BVXV Stock Price Chart Interactive Chart >

Price chart for BVXV

BVXV Price/Volume Stats

Current price $2.30 52-week high $22.90
Prev. close $2.34 52-week low $2.03
Day low $2.25 Volume 6,298
Day high $2.36 Avg. volume 193,466
50-day MA $2.49 Dividend yield N/A
200-day MA $7.87 Market Cap 4.30M

BiondVax Pharmaceuticals Ltd. (BVXV) Company Bio


Biondvax Pharmaceuticals Limited is a pharmaceutical company that develops intra-nasal flu vaccines.


BVXV Latest News Stream


Event/Time News Detail
Loading, please wait...

BVXV Latest Social Stream


Loading social stream, please wait...

View Full BVXV Social Stream

Latest BVXV News From Around the Web

Below are the latest news stories about BIONDVAX PHARMACEUTICALS LTD that investors may wish to consider to help them evaluate BVXV as an investment opportunity.

BiondVax to Present at BIO-Europe Spring

JERUSALEM, March 16, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biopharmaceutical company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announces today that its CEO Amir Reichman will be presenting in-person at the 17th annual BIO-Europe Spring taking place March 20–22, 2023, in Basel, Switzerland. The event is expected to bring toge

Yahoo | March 16, 2023

IBN Highlights 'Test. Optimize. Scale.' Episode Featuring BiondVax Pharmaceuticals Ltd. CEO Amir Reichman

LOS ANGELES, CA - (NewMediaWire) - March 06, 2023 - (InvestorBrandNetwork via NewMediaWire) - Multifaceted financial news and publishing company IBN today announces the release of the latest episode of the popular Test. The episode is hosted by Jason Fishman of Digital Niche Agency.

Yahoo | March 6, 2023

IBN Announces ‘Test. Optimize. Scale.’ Interview with BiondVax Pharmaceuticals Ltd. CEO Amir Reichman Discussing De-Risked Development Pipeline and Strategic Partnerships with Premier European Research Institutes

LOS ANGELES, March 03, 2023 (GLOBE NEWSWIRE) -- via InvestorWire -- IBN, a multifaceted financial news and publishing company for private and public entities, today announces that Amir Reichman, CEO of biotechnology company BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV), recently appeared on the popular Test. Optimize. Scale., a podcast series featuring industry leaders and pioneers sharing insights and experiences of growing their businesses to scale. The broadcast, hosted by Jason Fishman, SVP D

Yahoo | March 3, 2023

BiondVax Presenting at BIO CEO & Investor Conference

JERUSALEM, Feb. 02, 2023 (GLOBE NEWSWIRE) -- via InvestorWire – BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV), a biotechnology company focused on developing, manufacturing, and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, announced today that its CEO Amir Reichman will present at the BIO CEO & Investor Conference. The conference is taking place Feb. 6-9, 2023, in New York. Reichman’s presentation will focus on recent succ

Yahoo | February 2, 2023

BiondVax Touts Additional Preclinical Data From Inhaled COVID-19 Treatment Candidate

BiondVax Pharmaceuticals Ltd (NYSE: BVXV) announced additional results in a preclinical proof-of-concept study of its innovative inhaled NanoAb COVID-19 drug. The study compared weight loss in two groups of hamsters. Hamsters administered a mid-sized 0.66mg dose of the NanoAb three hours before infection experienced no significant weight loss over the six-day trial. But the untreated control group's weight declined 12% on average, a highly statistically significant difference. The prophylactic r

Yahoo | January 23, 2023

Read More 'BVXV' Stories Here

BVXV Price Returns

1-mo -1.71%
3-mo -29.45%
6-mo -76.13%
1-year -82.31%
3-year -96.29%
5-year -96.25%
YTD -22.30%
2022 -87.40%
2021 -16.37%
2020 -69.75%
2019 94.76%
2018 -11.01%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.7089 seconds.